Takeda Buys Out Partner GammaDelta In Cell Therapy Push
Lead Asset Newly In Phase I
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
You may also be interested in...
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Japan's largest pharma firm logs what was generally viewed by analysts as a solid fiscal third quarter, driven by growth for its portfolio of global products, leading to raised guidance for the full year despite one pipeline setback. There will also be multiple C-suite reshuffles come 1 April.
Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming and new updates from multiple Asian companies.